|
1
|
Gelderblom H, Hogendoorn PC, Dijkstra SD,
van Rijswijk CS, Krol AD, Taminiau AH and Bovée JV: The clinical
approach towards chondrosarcoma. Oncologist. 13:320–329. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fiorenza F, Abudu A, Grimer RJ, Carter SR,
Tillman RM, Ayoub K, Mangham DC and Davies AM: Risk factors for
survival and local control in chondrosarcoma of bone. J Bone Joint
Surg Br. 84:93–99. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Italiano A, Mir O, Cioffi A, Palmerini E,
Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz
JE, Collard O, Bertucci F, Bompas E, Le Cesne A, Maki RG, Ray
Coquard I and Blay JY: Advanced chondrosarcomas: role of
chemotherapy and survival. Ann Oncol. 24:2916–2922. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Onishi AC, Hincker AM and Lee FY:
Surmounting chemotherapy and radioresistance in chondrosarcoma:
molecular mechanisms and therapeutic targets. Sarcoma.
2011:3815642011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perez J, Decouvelaere AV, Pointecouteau T,
Pissaloux D, Michot JP, Besse A, Blay JY and Dutour A: Inhibition
of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic
rat model. PLoS One. 7:e324582012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang S, Konorev EA, Kotamraju S, Joseph J,
Kalivendi S and Kalyanaraman B: Doxorubicin induces apoptosis in
normal and tumor cells via distinctly different mechanisms:
intermediacy of H2O2- and p53-dependent
pathways. J Biol Chem. 279:25535–25543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Finn NA, Findley HW and Kemp ML: A
switching mechanism in doxorubicin bioactivation can be exploited
to control doxorubicin toxicity. PLoS Comput Biol. 7:e10021512011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gilliam LA, Moylan JS, Patterson EW, Smith
JD, Wilson AS, Rabbani Z and Reid MB: Doxorubicin acts via
mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am J
Physiol Cell Physiol. 302:C195–C202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Efferth T, Giaisi M, Merling A, Krammer PH
and Li-Weber M: Artesunate induces ROS-mediated apoptosis in
doxorubicin-resistant T leukemia cells. PLoS One. 2:e6932007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Zhou F, Wu X, Zhang X, Chen Y,
Zha BS, Niu F, Lu M, Hao G, Sun Y, Sun J, Peng Y and Wang G:
Cellular pharmacokinetic mechanisms of adriamycin resistance and
its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells. Br J
Pharmacol. 165:120–134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
12
|
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian
Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J and Chen X: A
small-molecule inhibitor of glucose transporter 1 downregulates
glycolysis, induces cell-cycle arrest, and inhibits cancer cell
growth in vitro and in vivo. Mol Cancer Ther.
11:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao X, Fang L, Gibbs S, Huang Y, Dai Z,
Wen P, Zheng X, Sadee W and Sun D: Glucose uptake inhibitor
sensitizes cancer cells to daunorubicin and overcomes drug
resistance in hypoxia. Cancer Chemotherapy Pharmacol. 59:495–505.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakano A, Tsuji D, Miki H, Cui Q, El Sayed
SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa
K, Takeuchi K, Sakai A, Ozaki S, Okano K, Nakamura T, Itoh K,
Matsumoto T and Abe M: Glycolysis inhibition inactivates ABC
transporters to restore drug sensitivity in malignant cells. PloS
One. 6:e272222011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou GQ, Tang LL, Mao YP, Chen L, Li WF,
Sun Y, Liu LZ, Li L, Lin AH and Ma J: Baseline serum lactate
dehydrogenase levels for patients treated with intensity-modulated
radiotherapy for nasopharyngeal carcinoma: a predictor of poor
prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol
Phys. 82:e359–e365. 2012. View Article : Google Scholar
|
|
16
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP and
Tan M: Warburg effect in chemosensitivity: targeting lactate
dehydrogenase-A re-sensitizes taxol-resistant cancer cells to
taxol. Mol Cancer. 9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Van Oosterwijk JG, Herpers B, Meijer D,
Briaire-de Bruijn IH, Cleton-Jansen AM, Gelderblom H, van de Water
B and Bovée JV: Restoration of chemosensitivity for doxorubicin and
cisplatin in chondrosarcoma in vitro: BCL-2 family members
cause chemoresistance. Ann Oncol. 23:1617–1626. 2012.PubMed/NCBI
|
|
18
|
Zaja R, Caminada D, Loncar J, Fent K and
Smital T: Development and characterization of P-glycoprotein 1
(Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish
cell line. Toxicol Appl Pharmacol. 227:207–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Latorre E, Tebaldi T, Viero G, Spartà AM,
Quattrone A and Provenzani A: Downregulation of HuR as a new
mechanism of doxorubicin resistance in breast cancer cells. Mol
Cancer. 11:132012. View Article : Google Scholar : PubMed/NCBI
|
